West Virginia v. Purdue Pharma: Nuisance Claim Revived on Remand

The Fourth Circuit’s ruling on the Huntington opioid distributors revived a lawsuit that the three largest U.S. drug wholesalers had won at trial, vacating a 2022 defense verdict and sending the case back to the district court with instructions to apply corrected legal standards. The October 28, 2025 decision found that the trial judge had misread West Virginia nuisance law, understated the distributors’ federal obligations, mishandled the causation analysis, and taken too narrow a view of what an abatement remedy can include.¹

The Case Behind the Appeal

The City of Huntington and Cabell County sued AmerisourceBergen, Cardinal Health, and McKesson over opioid shipments into a community of about 100,000 people. From 1997 through 2018, the three distributors sent at least 81.2 million dosage units of opioids into the area, and together supplied 89 percent of the oxycodone that reached it during that period.²

The local governments pursued a single legal theory: public nuisance. Under West Virginia common law, a public nuisance is an act or condition that unreasonably hurts or inconveniences a large number of people. The plaintiffs argued the distributors’ shipping volumes interfered with public health on a community-wide scale, and that the companies had failed to flag and report suspicious pharmacy orders as federal law required.¹

The distributors answered that they operated inside a tightly regulated supply chain, moving FDA-approved medications from manufacturers to licensed pharmacies filling prescriptions written by licensed physicians. They pointed to doctors, pharmacists, and criminal diverters as the real causes of the crisis, and argued public nuisance law was never meant to reach the sale of a lawful product.

The 2022 Trial Court Ruling

After a bench trial, U.S. District Judge David Faber ruled for the three distributors in July 2022. He gave four reasons. West Virginia law, in his reading, did not recognize public nuisance claims based on the sale and distribution of products. Even if it did, the plaintiffs had not proved the elements. The distributors’ conduct did not proximately cause the crisis. And the plaintiffs’ proposed abatement plan was not a proper remedy.³

On causation, Judge Faber pointed to doctors and criminal diverters as the real drivers of the epidemic. He read West Virginia’s proximate cause standard to require that wrongful conduct be the “last negligent act contributing to the injury,” and concluded that prescribing physicians and intervening criminal acts had severed the link between shipping decisions and community harm. He also rejected the plaintiffs’ roughly $2.5 billion abatement request, reasoning that the traditional nuisance remedy is an order to stop the conduct, and that what the plaintiffs really wanted was damages.

What the Fourth Circuit Changed

A three-judge panel found legal errors in nearly every major piece of the trial court’s analysis and vacated the ruling.

Public Nuisance Can Reach Controlled-Substance Distribution

The Fourth Circuit held that West Virginia common law does not categorically bar public nuisance claims arising from the distribution of controlled substances. When the distribution of a product unreasonably hurts or inconveniences a large, indefinite number of people, it can qualify as a public nuisance. The district court’s blanket conclusion that nuisance law simply could not reach lawful product sales was wrong as a matter of West Virginia law.¹

The Distributors’ Federal Duties Were Read Too Narrowly

The appellate court found that Judge Faber had construed the distributors’ obligations under the Controlled Substances Act too narrowly. Registered distributors must design and operate systems to identify suspicious orders of controlled substances and report them to the DEA. The law defines suspicious orders as those of unusual size, those that deviate substantially from a normal pattern, and those placed with unusual frequency, though it sets no numerical caps.⁴

The trial court had essentially asked whether pharmacies were operating as fronts for the illegal drug market. The Fourth Circuit held the actual duty is more granular: distributors must examine each individual order from each pharmacy for signs of diversion. That matters because the district court’s findings on unreasonable conduct and causation were built on the narrower, incorrect standard.¹

Intervening Actors Do Not Automatically Break the Chain

The panel rejected the idea that doctors, pharmacists, and criminal diverters were, as a matter of law, intervening causes that cut off liability. Under West Virginia law, a wrongdoer is not relieved by the acts of third parties if those acts were reasonably foreseeable. The trial court never evaluated whether it was foreseeable that excessive shipments would lead to overprescribing or diversion. That analysis has to happen on remand, with attention to evidence that the distributors repeatedly raised their own internal order thresholds and had access to dispensing data showing which prescribers were outliers.¹

Abatement Can Include Funding Remediation

Finally, the court disagreed that abatement is limited to telling a defendant to stop. An abatement plan requiring the distributors to fund remediation of the conditions they helped create is not automatically a disguised damages award. If the case reaches that stage on remand, the district court must evaluate the plaintiffs’ proposed plan on its merits and may modify or reduce it as equity requires.¹

Why the State Supreme Court Didn’t Weigh In

Before issuing its opinion, the Fourth Circuit tried to get guidance from West Virginia’s highest court, certifying a question about whether conditions caused by controlled-substance distribution can constitute a public nuisance under state common law, and if so, what elements such a claim requires.⁵ The West Virginia Supreme Court of Appeals declined to answer, reasoning that the question was too abstract while key factual findings were still being challenged, and that answering would amount to an advisory opinion. With no state court guidance available, the Fourth Circuit decided the state-law question itself.¹

What the Remand Means

The case returns to the district court with instructions to apply the correct legal standards. The lower court must reexamine whether the distributors unreasonably interfered with a public right using the broader view of their federal obligations, and must reassess causation with the foreseeability question in view. None of this guarantees the plaintiffs will win. The Fourth Circuit itself acknowledged that causation gaps may still exist in the record. But the case is no longer over.¹

One boundary is worth noting. This litigation sits alongside a separate nationwide settlement in which AmerisourceBergen, Cardinal Health, and McKesson collectively agreed to pay up to $21 billion over 18 years to resolve opioid claims from state and local governments across the country. Combined with a separate Johnson & Johnson settlement of up to $5 billion, the package reaches roughly $26 billion, with payments to participating governments beginning in 2022.⁶ That settlement resolved broad claims from thousands of communities but does not foreclose individual cases like Huntington’s from proceeding to a decision on distributor accountability.

1
United States Court of Appeals for the Fourth Circuit. City of Huntington v. AmerisourceBergen Drug Corporation
2
West Virginia Judiciary. City of Huntington and Cabell County Commission v. AmerisourceBergen Drug Corp. – Petitioners’ Brief
3
Justia. City of Huntington and Cabell County Commission v. AmerisourceBergen Drug Corporation
4
Drug Enforcement Administration Diversion Control Division. Suspicious Orders (SORS) Q&A
5
West Virginia Judiciary. City of Huntington and Cabell County Commission v. AmerisourceBergen Drug Corp. – Concurring Opinion
6
National Association of Attorneys General. Opioids